Stock analysis, trade plans, and proprietary indicators by Trend Edge.
Turn Therapeutics Inc., operates as a pharmaceuticals company that develops drugs to treat diseases of the skin, nails, and eye. The company's delivery technology penetrates the skin and nails and reduces antibiotic through acute and chronic wound care products, enabling healthcare institutions to care for a variety of skin conditions, ranging from acute to chronic wounds, skin conditions, and dermatoses. Read full Trend Edge analysis →
| Current Price | $5.31 |
|---|---|
| Market Cap | $148M |
| Float | 11.1M |
| Shares Outstanding | 29.8M |
| Dividend Rate | None |
| Year | Revenue | Net Income | Gross Profit | EBITDA |
|---|---|---|---|---|
| 2023 | N/A | -$2.3M | N/A | -$2.3M |
| 2024 | N/A | -$1.8M | N/A | -$1.7M |
| 2025 | N/A | -$3.2M | N/A | -$5.8M |
| Quarter | Revenue | Net Income |
|---|---|---|
| Jun 2025 | N/A | -$1.2M |
| Sep 2025 | N/A | -$1.9M |
| Dec 2025 | N/A | $279,070 |
| Mar 2026 | N/A | -$970,972 |
| Insider Ownership | 63.7% |
|---|---|
| Institutional Ownership | 1.7% |
| Short Float | 0.5% |
| % of All Funds Holding | 0.23% |
| Number of Funds Holding | 19 |
Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.
| Timeframe | SMA | Value | Trend Context |
|---|---|---|---|
| Weekly | 10-Week SMA | $3.92 | Near-term / short-term trend |
| Weekly | 40-Week SMA | $0.00 | Medium-term trend |
| Weekly | 80-Week SMA | $0.00 | Cyclical trend (business cycle) |
| Weekly | 200-Week SMA | $0.00 | Secular trend (multi-year) |
| Monthly | 10-Month SMA | $0.00 | Near-term monthly trend |
| Monthly | 20-Month SMA | $0.00 | Medium-term monthly trend |
| Monthly | 40-Month SMA | $0.00 | Secular monthly trend |
Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.
Volume shelf data not available.
| Timeframe | Avg Return | Median | Win Rate | Best | Worst |
|---|---|---|---|---|---|
| Gap | -2.65% | -2.97% | 0.00% | -1.80% | -3.18% |
| 1 Day | -0.76% | -2.20% | 33.33% | 2.58% | -2.66% |
| 1 Week | 2.30% | 9.69% | 66.67% | 17.27% | -20.05% |
| 2 Weeks | 9.59% | 6.87% | 66.67% | 36.34% | -14.43% |
| 1 Month | -5.85% | -5.85% | 50.00% | 15.94% | -27.63% |
Next earnings: August 13, 2026 (76 days away)
Insufficient historical data for monthly seasonality analysis (requires 7+ years of data).
Institutional holder breakdown coming soon.
Total institutional ownership: 1.7%
Total insider ownership: 63.7%
Founder-led management: Bradley Burnam (Chief Executive Officer & Founder)
| Total Filings | 8 |
|---|---|
| Net Value | +$49,872.12 |
| Net Shares Change | 77,388 |
| % of Float | 0.7% |
| C-Suite Filings | 4 |
| Clusters Detected | 1 |
| Name | Title | Net Value | Filings | Activity |
|---|---|---|---|---|
| GOLDEN ARTHUR F | +$192,872.66 | 3 | 3 buy | |
| Chesed Abraham | +$65,715.6 | 1 | 1 buy | |
| Chaudhary Zuraiz | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer. | +$49,872.12 | 4 | 4 buy |
| Period | Filings | Insiders | Net Value | Seniority |
|---|---|---|---|---|
| 2025-10-23 – 2025-10-29 | 3 | 3 | +$190,713 | 1 C-suite |
| Date | Insider | Title | Net Value | Price After |
|---|---|---|---|---|
| 2025-12-12 | Chaudhary Zuraiz | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer. | +$8,750 | Transaction at $3.50, now +51.7% |
| 2025-11-21 | Chaudhary Zuraiz | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer. | +$7,074.62 | Transaction at $2.89, now +83.9% |
| 2025-11-17 | Chaudhary Zuraiz | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer. | +$9,050 | Transaction at $3.62, now +46.7% |
| 2025-10-23 | Chaudhary Zuraiz | Interim Chief Financial Officer, Vice President of Finance and Chief Accounting Officer. | +$24,997.5 | Transaction at $4.95, now +7.3% |
| 2025-11-25 | GOLDEN ARTHUR F | +$33,945.92 | Transaction at $3.44, now +54.4% | |
| 2025-11-24 | GOLDEN ARTHUR F | +$58,926.84 | Transaction at $2.87, now +85.0% |
Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Turn Therapeutics Inc. Common Stock (TTRX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).
AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.
Get the full AI Consult analysis for TTRX on Trend Edge →